Get started
Author

Gregory A. Sahagian

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
2021 · James F Howard, Vera Bril, et al. · The Lancet Neurology · 743
Randomized Double-blind Study Comparing the Efficacy of Gabapentin With Amitriptyline on Diabetic Peripheral Neuropathy Pain
1999 · Candis M. Morello, Susan G. Leckband, et al. · Archives of Internal Medicine · 445
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
2023 · Volkan Granit, Michael Benatar, et al. · The Lancet Neurology · 281
Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies
2024 · Christopher H. Gibbons, Todd Levine, et al. · JAMA · 198
PDF
Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
2015 · Enchi Liu, Mark E. Schmidt, et al. · Neurology · 151
PDF
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
2020 · Jacqueline Palace, Dean M. Wingerchuk, et al. · Multiple Sclerosis and Related Disorders · 41
PDF
Modulation of the insulin growth factor II/mannose 6-phosphate receptor in microvascular endothelial cells by phorbol ester via protein kinase C.
1990 · K.Q. Hu, J.M. Backer, et al. · Journal of Biological Chemistry · 32
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial
2026 · Tuan Vu, Hacer Durmus, et al. · Nature Medicine · 31
Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension
2023 · Richard J. Nowak, Ari Breiner, et al. · Annals of Clinical and Translational Neurology · 21
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
2026 · Renee R. Fedak, Rachel N. Ruggerie, et al. · Nature Medicine · 20
PDF
Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
2025 · Nizar Chahin, Gregory Sahagian, et al. · Annals of Clinical and Translational Neurology · 18
PDF
ADAPT NXT : Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
2025 · Ali A. Habib, Kristl G. Claeys, et al. · Annals of Clinical and Translational Neurology · 18
PDF
Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy
2024 · Nizar Chahin, Gregory Sahagian, et al. · medRxiv · 15
PDF
A functional neuroimaging biomarker of mild cognitive impairment using TD-fNIRS
2025 · Julien Dubois, John Gregory Duffy, et al. · npj Dementia · 8
PDF
Molecular Gene Expression Testing to Identify Alzheimer’s Disease with High Accuracy from Fingerstick Blood
2024 · Bruce Seligmann, Salvatore Camiolo, et al. · Journal of Alzheimer s Disease · 6
Fixed-cycle and Continuous Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT (P10-11.010)
2024 · Vera Bril, Yessar Hussain, et al. · Neurology · 5
Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia
2025 · Christopher H. Gibbons, Todd Levine, et al. · Annals of Clinical and Translational Neurology · 4
PDF
Efficacy and Safety of Autologous BCMA-directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis: Results from a Phase 2b Randomized Placebo-controlled Trial (S34.002)
2025 · Tuan Vu, Hacer Durmus Tekce, et al. · Neurology · 2
Fixed Cycle and Q2W Dosing of Intravenous Efgartigimod for gMG: Part A of ADAPT NXT
2024 · Jonathan Bosold, Edward Brauer, et al. · Neurology · 2
Sustained Clinical Efficacy and Long-term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT (P9-9.003)
2026 · Arjun Seth, Yessar Hussain, et al. · Neurology
Implementing the CMS GUIDE Dementia Care Model in a Community Neurology Practice with Digital Tools, Standardized Scales, and Embedded Clinical Trial Recruitment (P5-12.011)
2026 · Gregory Sahagian, Vidar Vignisson, et al. · Neurology
22194 - Administración De Efgartigimod Intravenoso En Ciclos Fijos Y Cada Dos Semanas En Miastenia Gravis Generalizada (mgg): Parte B De Adapt Nxt
2025 · E. Cortés Vicente, K. Gwathmey, et al. · Neurology Perspectives
Abstract 6202: Liquid biopsy multi-omic TempO-Seq platform for efficacy, safety, diagnosis, and subtyping using fingerstick blood
2025 · Bruce Seligmann, Megan Opichka, et al. · Cancer Research
Efficacy and Safety of Autologous BCMA-directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis: Results from a Phase 2b Randomized Placebo-controlled Trial
2025 · Vu, Tuan, Tekce, Hacer Durmus, et al.
PDF
Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT (P1-11.004)
2025 · Kelly Gwathmey, Vera Bril, et al. · Neurology
Works count: 36
Citation count: 2,039
H-index: 13
I10-index: 13
Year
Topic
Type